These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26447503)

  • 1. Bioresorbable scaffolds in daily clinical routine: a practical review of all-comers results.
    Wiebe J; Hamm CW; Nef HM
    Curr Opin Cardiol; 2015 Nov; 30(6):650-6. PubMed ID: 26447503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation.
    Wiebe J; Dörr O; Liebetrau C; Bauer T; Wilkens E; Ilstad H; Boeder N; Elsässer A; Möllmann H; Hamm CW; Nef HM
    Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1144-1151. PubMed ID: 28134094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry.
    Ortega-Paz L; Capodanno D; Giacchi G; Gori T; Nef H; Latib A; Caramanno G; Di Mario C; Naber C; Lesiak M; Capranzano P; Wiebe J; Mehilli J; Araszkiewicz A; Pyxaras S; Mattesini A; Geraci S; Naganuma T; Colombo A; Münzel T; Sabaté M; Tamburino C; Brugaletta S
    Catheter Cardiovasc Interv; 2017 Apr; 89(5):812-818. PubMed ID: 27515568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioresorbable vascular scaffolds in left main coronary artery disease.
    Everaert B; Capranzano P; Tamburino C; Seth A; van Geuns RJ
    EuroIntervention; 2015; 11 Suppl V():V135-8. PubMed ID: 25983148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up and predictors of target lesion failure after implantation of everolimus-eluting bioresorbable scaffolds in real-world practice.
    Wiebe J; Baquet M; Dörr O; Hoppmann P; Jochheim D; Rheude T; Boeder N; Grundmann D; Blachutzik F; Theiss H; Cassese S; Hofmann FJ; Gschwendtner S; Elsässer A; Massberg S; Hamm C; Laugwitz KL; Byrne RA; Mehilli J; Kastrati A; Nef H
    Int J Cardiol; 2020 Aug; 312():42-47. PubMed ID: 32151443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expansion in calcific lesions and overall clinical outcomes following bioresorbable scaffold implantation optimized with intravascular ultrasound.
    Kawamoto H; Ruparelia N; Latib A; Miyazaki T; Sato K; Tanaka A; Naganuma T; Sticchi A; Chieffo A; Carlino M; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2017 Apr; 89(5):789-797. PubMed ID: 27545845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioresorbable scaffold implantation in patients with indication for oral anticoagulation: A propensity matched analysis.
    Boeder NF; Johnson V; Dörr O; Wiebe J; Elsässer A; Möllmann H; Hamm CW; Nef HM; Bauer T
    Int J Cardiol; 2017 Mar; 231():73-77. PubMed ID: 27899203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary Report of Clinical Outcomes After Single Crossover Bioresorbable Scaffold Implantation Without Routine Side Branch Strut Dilation.
    Tanaka A; Jabbour RJ; Kawamoto H; Mangieri A; Pagnesi M; Montalto C; Chieffo A; Carlino M; Montorfano M; Latib A; Colombo A
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):865-870. PubMed ID: 27219102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weighing the potential late benefits versus early hazard associated with bioresorbable vascular scaffolds in percutaneous coronary interventions: a Markov decision analytic model.
    Fazel R; Vilain KA; Cohen DJ; Yeh RW
    Coron Artery Dis; 2020 May; 31(3):230-236. PubMed ID: 31658137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paving the way to a bioresorbable technology: Development of the absorb BRS program.
    Perkins LE; Kossuth MB; Fox JC; Rapoza RJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):1-9. PubMed ID: 27797462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome.
    Nef HM; Wiebe J; Schmidt G; Möllmann H; Boeder NF; Dörr O; Bauer T; Blachutzik F; Liebetrau C; Elsässer A; Foin N; Hamm CW
    Herz; 2020 Dec; 45(Suppl 1):95-104. PubMed ID: 31209520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design Principles of Bioresorbable Polymeric Scaffolds.
    Kossuth MB; Perkins LEL; Rapoza RJ
    Interv Cardiol Clin; 2016 Jul; 5(3):349-355. PubMed ID: 28582032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Strut Width in Periprocedural Myocardial Infarction: A Propensity-Matched Comparison Between Bioresorbable Scaffolds and the First-Generation Sirolimus-Eluting Stent.
    Kawamoto H; Panoulas VF; Sato K; Miyazaki T; Naganuma T; Sticchi A; Figini F; Latib A; Chieffo A; Carlino M; Montorfano M; Colombo A
    JACC Cardiovasc Interv; 2015 Jun; 8(7):900-9. PubMed ID: 26003020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioresorbable Scaffolds: Clinical Outcomes and Considerations.
    Capodanno D
    Interv Cardiol Clin; 2016 Jul; 5(3):357-363. PubMed ID: 28582033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioresorbable vascular scaffold in patients with complex coronary artery disease.
    Tamburino CI; Capranzano P; Longo G; Immè S; Tamburino G; Scalia M; Condorelli A; Francaviglia B; LA Manna A; Sgroi C; Grasso C; DI Salvo ME; Capodanno D; Tamburino C
    Minerva Cardioangiol; 2016 Aug; 64(4):481-6. PubMed ID: 27128353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design.
    Woudstra P; Grundeken MJ; Kraak RP; Hassell ME; Arkenbout EK; Baan J; Vis MM; Koch KT; Tijssen JG; Piek JJ; de Winter RJ; Henriques JP; Wykrzykowska JJ
    Am Heart J; 2014 Feb; 167(2):133-40. PubMed ID: 24439973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future perspectives on drug-eluting bioresorbable coronary scaffolds.
    Ielasi A; Tespili M
    Future Cardiol; 2014 May; 10(3):409-20. PubMed ID: 24976477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life data regarding acute procedural success and 1-year clinical outcome of desolve bioresorbable scaffolds.
    Gunes HM; Gokdeniz T; Kizilirmak Yilmaz F; Demir GG; Guler E; Babur Guler G; Karaca O; Cakal B; Omaygenç MO; İbişoğlu E; Boztosun B
    J Interv Cardiol; 2017 Jun; 30(3):189-194. PubMed ID: 28440067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When and how to use BRS in bifurcations?
    Stankovic G; Lassen JF
    EuroIntervention; 2015; 11 Suppl V():V185-7. PubMed ID: 25983163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioresorbable scaffold -fourth revolution or failed revolution: Is low scaffold strut thickness the wrong target?
    Mishra S
    Indian Heart J; 2017; 69(6):687-689. PubMed ID: 29174242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.